Oppenheimer analyst Suraj Kalia has increased the price target for Abbott Laboratories (ABT, Financial) from $134 to $140, maintaining an Outperform rating for the company. This adjustment follows a review of the company's latest quarterly results.
The analyst's optimistic stance is based on the expectation that challenges outside the medical technology sector will lessen. Additionally, Abbott's sales comparisons are anticipated to become more favorable by fiscal year 2026. This, combined with expected low double-digit growth in top-line revenue and improved EBIT margins, supports the elevated price target.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $140.41 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 8.25% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
